Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on February 5, 2013. The report addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements. The company is incorporated in Delaware and headquartered in Redwood City, California.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
| Named Executive Officer | 2013 Base Salary | 2012 Bonus Payment |
|---|---|---|
| Richard A. King, CEO | $475,000 | $170,400 |
| James H. Welch, CFO | $307,500 | $95,232 |
| Pamela P. Palmer, CMO | $409,000 | $134,034 |
| Badri Dasu, Chief Engineering Officer | $301,500 | $95,160 |
| Lawrence G. Hamel, Chief Development Officer | $301,000 | $93,964 |
Material Changes
The Board of Directors approved 2013 base salaries for five named executive officers, effective retroactively to January 1, 2013. Additionally, the Board approved 2012 performance bonus payments in accordance with the Company's established 2012 Cash Bonus Plan.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items. The document is strictly a disclosure of executive compensation decisions.
Investor Verification Points
- Confirm the retroactive effective date of January 1, 2013, for the new base salaries.
- Verify the total cash outflow for the 2012 bonus payments totaling approximately $588,790.
- Review the Company's 2012 Cash Bonus Plan to understand the performance metrics triggering these payments.